A nomogram could help to predict patients at risk of Grade 4 neutropenia during treatment, according to a study published in Clinical Genitourinary Cancer.
A nomogram could help to predict patients at risk of Grade 4 neutropenia during treatment, according to a study published in Clinical Genitourinary Cancer.
Nomograms are used in oncology as prediction tools to help patients and physicians make treatment decisions. The device uses an alpha-numeric code to describe something unique about the patient: genetic makeup, tumor makeup, comorbidities, social environment, etc.
Researchers from Tokyo Medical University in Japan studied 112 patients with castration-resistant prostate cancer (CRPC) who were treated with docetaxel-based systemic chemotherapy. Neutropenia is a major adverse event of docetaxel-based chemotherapy and the researchers sought to develop a nomogram for predicting Grade 4 neutropenia during the first cycle of chemotherapy.
More than half (55.4%) of the patients developed Grade 4 neutropenia in the first cycle of docetaxel-based chemotherapy. The researchers noted that there were significant differences in age, baseline white blood cell count, and baseline neutrophil count among patients with non-Grade 4 neutropenia and those with Grade 4 neutropenia.
However, there were not significant differences between the 2 groups when it came to serum prostate-specific antigen level, hemoglobin level, creatinine, albumin, Eastern Cooperative Oncology Group performance status, metastatic sites, extent of disease, and history of external beam radiotherapy to the prostate.
As a result, the researchers determined that age and baseline neutrophil counts were significant independent risk factors for severe neutropenia.
“Age and baseline neutrophil counts were significant independent risk factors for Grade 4 neutropenia,” the authors concluded. “The nomogram to predict it provides useful information for the management of patients with CRPC treated with docetaxel chemotherapy.”
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Study Reveals Link Between Ovarian Cancer, Subsequent Dry Eye Disease Incidence
May 13th 2024Patients diagnosed with ovarian cancer (OC), particularly those older than 60 years or with a disease duration exceeding 5 years, had a higher incidence of subsequent dry eye disease (DED), suggesting a potential correlation between OC and DED.
Read More